Mascoma Wealth Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Mascoma Wealth Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,000	Closed	-$61.6K	–	514
2023 Q3	$61.6K	Hold	5,000	–	–	0.02%	166
2023 Q2	$61.1K	Hold	5,000	–	–	0.02%	176
2023 Q1	$62K	Hold	5,000	–	–	0.02%	214
2022 Q4	$57.3K	Hold	5,000	–	–	0.02%	214
2022 Q3	$19K	Hold	5,000	–	–	0.01%	334
2022 Q2	$30K	Hold	5,000	–	–	0.01%	303
2022 Q1	$32K	Hold	5,000	–	–	0.01%	323
2021 Q4	$20K	Hold	5,000	–	–	0.01%	334
2021 Q3	$24K	Buy	+5,000	New	+$26.1K	0.01%	277
2021 Q2	–	Sell	-5,000	Closed	-$31K	–	472
2021 Q1	$31K	Buy	+5,000	New	+$35.7K	0.01%	259
2017 Q3	–	Sell	-127	Closed	-$1K	–	429
2017 Q2	$1K	Buy	+127	New	+$2.59K	﹤0.01%	401

Other funds holding MACK

WSL

Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mascoma Wealth Management's MACK Position: Q4 2023 in Review

Mascoma Wealth Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2023, closing a stake of 5,000 shares — an estimated $61.6K sold.

Mascoma Wealth Management first reported a position in MACK in Q2 2017 and held it in 11 quarters. The position peaked at $62K in Q1 2023. 67 funds tracked by Wall St. Rank hold MACK as of Q4 2023.

Mascoma Wealth Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Mascoma Wealth Management sold 5,000 Merrimack Pharmaceuticals, Inc. shares in Q4 2023, an estimated $61.6K.
Mascoma Wealth Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 11 quarters.
Mascoma Wealth Management's Merrimack Pharmaceuticals, Inc. position peaked at $62K in Q1 2023.
67 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2023.

Based on Mascoma Wealth Management's 13F filing for Q4 2023, filed 24 Jan 2024.